Advertisement
Screener

ZAI LAB LIMITED (ZLAB) EBITDA

Zai Lab Ltd EBITDA

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of the cash a company's operations generate before accounting charges for wearing out its assets. Here it is operating income plus the filed depreciation and amortization, not a figure the company adjusted itself. Higher EBITDA means more operating profit before those charges. It is not an official accounting (GAAP) measure and does not subtract capital spending, interest or tax, so it does not show what those obligations cost.

  • Zai Lab Ltd ebitda for the quarter ending 2026-06-30 was -$72.32M, a change of -$21.16M year-over-year.
  • Zai Lab Ltd ebitda for the quarter ending 2026-03-31 was -$65.44M, a change of -$12.59M year-over-year.
  • Zai Lab Ltd ebitda for the quarter ending 2025-12-31 was -$65.49M, a change of -$631,000.00 year-over-year.
  • Zai Lab Ltd ebitda for the quarter ending 2025-09-30 was -$44.92M, a change of $20.06M year-over-year.
  • Zai Lab Ltd ebitda for fiscal 2025 was -$214.42M, a change of $55.84M from fiscal 2024.
  • Zai Lab Ltd ebitda for fiscal 2024 was -$270.26M, a change of $87.28M from fiscal 2023.
  • Zai Lab Ltd ebitda for fiscal 2023 was -$357.54M, a change of $38.59M from fiscal 2022.
  • Zai Lab Ltd ebitda for fiscal 2022 was -$396.13M, a change of $297.45M from fiscal 2021.
Available history
2015-12-31 to 2026-06-30
Data captured

Historical EBITDA

EBITDA 3 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2026-06-30Reported-$72.32M-$76.49M$4.17M$105.75M-68.38%$1.31M*-$63.41M*$48.16M$61.77M$72.87M-$1.02M
2026-03-31Reported-$65.44M-$69.39M$3.94M$95.56M-68.48%$1.20M-$11.91M$38.31M$65.59M$65.07M$1.44M
2025-12-31Reported-$65.49M-$69.41M$3.92M$127.09M-51.53%(m)(m)(m)(m)(m)(m)
2025-09-30Reported-$44.92M-$48.82M$3.9M$115.36M-38.94%$3.00M*-$32.04M*$46.76M$47.93M$70.11M$0.00
2025-06-30Reported-$51.16M-$54.9M$3.74M$109.09M-46.90%$2.88M*-$31.02M*$43.00M$50.61M$71.04M$0.00
2025-03-31Reported-$52.85M-$56.31M$3.46M$105.65M-50.03%$1.53M-$61.70M$38.45M$60.73M$63.42M$0.00
2024-12-31Reported-$64.86M-$67.89M$3.03M$108.51M-59.77%(m)(m)(m)(m)(m)(m)
2024-09-30Reported-$64.98M-$67.85M$2.87M$101.85M-63.80%$1.34M*-$26.82M*$36.57M$65.98M$67.22M$0.00
2024-06-30Reported-$73.12M-$76.06M$2.94M$100.11M-73.05%$741.00K*-$42.17M*$35.15M$61.63M$79.71M$0.00
2024-03-31Reported-$67.3M-$70.31M$3.01M$87.15M-77.22%$974.00K-$90.11M$33.62M$54.65M$69.19M$0.00
2023-12-31Reported-$121.52M-$123.98M$2.46M$65.83M-184.60%(m)(m)(m)(m)(m)(m)
2023-09-30Reported-$81.65M-$83.57M$1.92M$69.23M-117.95%$1.76M*-$55.27M*$25.48M$58.77M$68.55M$0.00
2023-06-30Reported-$87.51M-$89.5M$2M$68.86M-127.07%$1.72M*-$58.70M*$23.76M$76.68M$67.92M$0.00
2023-03-31Reported-$66.87M-$69.52M$2.66M$62.8M-106.48%$3.51M-$69.29M(m)$48.47M$62.51M$0.00
2022-12-31Reported-$95.17M-$97.29M$2.13M$62.04M-153.40%(m)(m)(m)(m)(m)(m)
2022-09-30Reported-$126.36M-$128.58M$2.23M$56.96M-221.82%$6.68M*-$126.32M*(m)$99.52M$66.56M$0.00
2022-06-30Reported-$96.86M-$98.72M$1.86M$47.58M-203.58%$3.75M*-$44.90M*(m)$66.08M$63.40M$0.00
2022-03-31Reported-$77.75M-$79.76M$2.01M$46.1M-168.68%$9.74M-$87.13M(m)$53.85M$56.99M$0.00
2021-12-31Reported-$217.32M-$219.2M$1.88M$43.96M-494.32%(m)(m)(m)(m)(m)(m)
2021-09-30Reported-$81.57M-$83.21M$1.64M$43.1M-189.24%$6.27M*-$160.89M*(m)$55.14M$59.00M$0.00
2021-06-30Reported-$169.04M-$170.57M$1.53M$36.94M-457.68%$3.96M*-$65.85M*(m)$142.22M$54.41M$0.00
2021-03-31Reported-$225.64M-$227.09M$1.45M$20.1M-1122.44%$1.68M-$169.50M(m)$203.85M$35.84M$0.00
2020-12-31Reported-$93.87M-$95.26M$1.39M$15.09M-621.90%(m)(m)(m)(m)(m)(m)
2020-09-30Reported-$75.11M-$76.26M$1.15M$14.65M-512.67%$3.53M*-$79.40M*(m)$58.10M$27.87M(m)
2020-06-30Reported-$82.93M-$83.97M$1.04M$11M-754.24%$260.00K*-$52.48M*(m)$68.31M$23.76M(m)
2020-03-31Reported-$45.25M-$46.32M$1.07M$8.22M-550.64%$1.04M-$39.84M(m)$33.74M$18.71M(m)
2019-12-31Reported-$50.76M-$52.05M$1.29M$4.65M-1092.76%(m)(m)(m)(m)(m)(m)
2019-09-30Reported-$64.35M-$65.27M$914,853.00$4.92M-1308.05%(m)(m)(m)(m)(m)(m)
2018-12-31Reported-$66.04M-$66.54M$499,459.00(m)(m)(m)(m)(m)(m)(m)(m)

EBITDA 12 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2025-12-31Reported-$214.42M-$229.43M$15.01M$457.18M-46.90%$8.10M-$150.79M$190.52M$220.90M$277.61M-$2.93M
2024-12-31Reported-$270.26M-$282.12M$11.86M$397.61M-67.97%$5.66M-$214.87M$147.12M$234.50M$298.74M$0.00
2023-12-31Reported-$357.54M-$366.57M$9.03M$266.72M-134.05%$7.21M-$198.18M$95.82M$265.87M$281.61M$0.00
2022-12-31Reported-$396.13M-$404.36M$8.23M$212.67M-186.26%$24.59M-$367.64M$74.02M$286.41M$258.97M$0.00
2022-09-30Rolling(m)-$526.26M*(m)$194.60M*(m)(m)(m)(m)(m)(m)(m)
2022-06-30Rolling(m)-$480.88M*(m)$180.74M*(m)(m)(m)(m)(m)(m)(m)
2022-03-31Rolling(m)-$552.74M*(m)$170.10M*(m)(m)(m)(m)(m)(m)(m)
2021-12-31Reported-$693.58M-$700.06M$6.49M$144.11M-481.30%$18.30M-$549.23M(m)$573.31M$218.83M$0.00
2021-12-31Rolling(m)-$700.06M*(m)$144.10M*(m)(m)(m)(m)(m)(m)(m)
2021-09-30Rolling(m)-$576.12M*(m)$115.23M*(m)(m)(m)(m)(m)(m)(m)
2021-06-30Rolling(m)-$569.18M*(m)$86.78M*(m)(m)(m)(m)(m)(m)(m)
2021-03-31Rolling(m)-$482.57M*(m)$60.84M*(m)(m)(m)(m)(m)(m)(m)
2020-12-31Reported-$297.16M-$301.8M$4.64M$48.96M-606.97%$10.13M-$216.06M(m)$222.71M$111.31M$0.00
2020-12-31Rolling(m)-$301.80M*(m)$48.96M*(m)(m)(m)(m)(m)(m)(m)
2019-12-31Reported-$199.43M-$203.2M$3.77M$12.99M-1535.85%$6.04M-$191.01M(m)$142.22M$70.21M$0.00
2018-12-31Reported-$140.12M-$141.77M$1.65M$129,000.00-108618.60%$10.02M-$97.54M(m)$120.28M$21.58M$0.00
2017-12-31Reported-$50.84M-$51.39M$548,000.00(m)(m)$9.10M-$32.37M(m)$39.34M$12.05M$0.00
2016-12-31Reported-$38.33M-$38.53M$199,005.00(m)(m)$2.22M-$32.16M(m)$32.15M$6.38M(m)
2015-12-31Reported-$16.22M-$16.35M$126,507.00(m)(m)$738.47K(m)(m)$13.59M(m)(m)

Similar stocks

Stock NameCountryMarket CapPE Ratio
Aurinia Pharmaceuticals Inc. (AUPH)$2.207B7.18
Prestige Consumer Healthcare Inc. (PBH)United States$2.163B13.03
OCULAR THERAPEUTIX, INC (OCUL)United States$2.159B-7.15
Viridian Therapeutics, Inc.\DE (VRDN)United States$2.342B-5.38
Mineralys Therapeutics, Inc. (MLYS)United States$2.353B-6.82
Bausch Health Companies Inc. (BHC)$2.113B-1.68
Braveheart Bio, Inc. (BRVE)United States$2.106B
PALVELLA THERAPEUTICS, INC. (PVLA)United States$2.105B-35.55
Trevi Therapeutics, Inc. (TRVI)United States$2.091B-51.93
Harmony Biosciences Holdings, Inc. (HRMY)United States$2.399B11.67